Difficulties and advancements in developing drugs for the treatment of dengue fever

Christian G. Noble, Pei-Yong Shi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.

Original languageEnglish (US)
Pages (from-to)947-949
Number of pages3
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number12
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Dengue
Dengue Virus
Pharmaceutical Preparations
Antiviral Agents
Virus Diseases
Drug Discovery
Therapeutics
Culicidae
Human Activities
Blood Vessels
Disease Progression
Pathology
Infection

Keywords

  • Antiviral
  • Dengue virus
  • Drug discovery
  • Flavivirus
  • Inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Difficulties and advancements in developing drugs for the treatment of dengue fever. / Noble, Christian G.; Shi, Pei-Yong.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 12, 2013, p. 947-949.

Research output: Contribution to journalReview article

@article{0c9f8e2013ee4e3b85e0999ce73144f2,
title = "Difficulties and advancements in developing drugs for the treatment of dengue fever",
abstract = "Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.",
keywords = "Antiviral, Dengue virus, Drug discovery, Flavivirus, Inhibitor",
author = "Noble, {Christian G.} and Pei-Yong Shi",
year = "2013",
doi = "10.1517/21678707.2013.858597",
language = "English (US)",
volume = "1",
pages = "947--949",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Difficulties and advancements in developing drugs for the treatment of dengue fever

AU - Noble, Christian G.

AU - Shi, Pei-Yong

PY - 2013

Y1 - 2013

N2 - Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.

AB - Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.

KW - Antiviral

KW - Dengue virus

KW - Drug discovery

KW - Flavivirus

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84896708349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896708349&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.858597

DO - 10.1517/21678707.2013.858597

M3 - Review article

VL - 1

SP - 947

EP - 949

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 12

ER -